1. GPCR/G Protein
  2. Glucagon Receptor

Adomeglivant (Synonyms: LY2409021; LY 2409021; LY-2409021)

Cat. No.: HY-19904
Handling Instructions

Adomeglivant is a potent and selective glucagon receptor antagonist that is used in clinical trial for type 2 diabetes mellitus.

For research use only. We do not sell to patients.
Adomeglivant Chemical Structure

Adomeglivant Chemical Structure

CAS No. : 1488363-78-5

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO $122 In-stock
5 mg $100 In-stock
10 mg $150 In-stock
25 mg $240 In-stock
50 mg $440 In-stock
100 mg $650 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Top Publications Citing Use of Products
  • Biological Activity

  • Protocol

  • Technical Information

  • References

Description

Adomeglivant is a potent and selective glucagon receptor antagonist that is used in clinical trial for type 2 diabetes mellitus.

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT02217618 Eli Lilly and Company Healthy Volunteers August 2014 Phase 1
NCT01929109 Eli Lilly and Company Kidney Failure, Chronic|Renal Insufficiency, Chronic August 2013 Phase 1
NCT02385084 Eli Lilly and Company Healthy March 2015 Phase 1
NCT02091362 Eli Lilly and Company Type 2 Diabetes Mellitus March 2014 Phase 2
NCT01640834 Eli Lilly and Company Diabetes Mellitus, Type 1 July 2012 Phase 1
NCT01460368 Eli Lilly and Company Diabetes Mellitus, Type 2 October 2011 Phase 1
NCT01588366 Eli Lilly and Company Diabetes Mellitus, Type 2 April 2012 Phase 1
NCT01606397 Eli Lilly and Company Diabetes Mellitus, Type 2 March 2008 Phase 1
NCT01836198 Eli Lilly and Company Healthy Volunteers May 2013 Phase 1
NCT01241448 Eli Lilly and Company Diabetes Mellitus, Type 2 January 2011 Phase 2
NCT02111096 Eli Lilly and Company Diabetes Mellitus, Type 2 April 2014 Phase 2
NCT01606423 Eli Lilly and Company Healthy Volunteers November 2007 Phase 1
NCT01606371 Eli Lilly and Company Diabetes Mellitus, Type 2 May 2007 Phase 1
NCT01354496 Eli Lilly and Company Healthy Volunteers April 2011 Phase 1
NCT00871572 Eli Lilly and Company Diabetes Mellitus, Type 2 March 2009 Phase 2
NCT02944110 University Hospital, Gentofte, Copenhagen|Eli Lilly and Company Diabetes After Total Pancreatectomy May 2016
NCT02669524 University Hospital, Gentofte, Copenhagen|Eli Lilly and Company Type 2 Diabetes October 2015
View MoreCollapse
References
M.Wt

555.63

Formula

C₃₂H₃₆F₃NO₄

CAS No.

1488363-78-5

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

DMSO: ≥ 5.3 mg/mL

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Adomeglivant
Cat. No.:
HY-19904
Quantity: